11/04/2004 13:53 FAX 7606033820

ISIS-PHARMACEUTICALS

→ HOWSON & HOWSON Ø 006/007

PTO/SB/80 (08-04)

Approved for use through 11/30/2005. OMB 0651-0035

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless à displays a valid OMB control number.

POWER OF ATTORNEY TO PROSECUTE APPLICATIONS BEFORE THE USPTO

ereby appo		36441		
_	ers associated with the Customer Numi			•
OR Practition	er(s) named below (if more than ten pa	itent practitioners are to be nam	ned. (hen a customer number mu	st be used):
	Name		Registration Nur	nber
		<u></u>		
-				
			<u> </u>	
ly and all pati tached to this	or agent(s) to rapresent the undersigner ent applications assigned only to the unside form in accordance with 37 CFR 3.73 (arme and Address:		ent and Trademark Office (USPT PTO assignment records or assi	O) In connection with gament documents
ssignee No	ent applications sassified on the storm in accordance with 37 CFR 3.736 ame and Address: 51S Pharmaceuticals, I 292 Faraday Avenue	(b).	ent and Trademark Office (USPT PTO assignment records or assi	O) In connection with gament documents
ny and all pat tached to this ssignee Ni IS 22	ent applications sassing to see form in accordance with 37 CFR 3.736 arme and Address: 51S Pharmaceuticals, I 292 Faraday Avenue arlsbad, California 9	nc. 2008	77/h) /Form PTO/SR/96 (or equivalent) Is
ny and an patriached to this ssignee No. 22 Co. A copy of to equired to	ent applications assigned and secondance with 37 CFR 3.736 ame and Address: 51S Pharmaceuticals, I 292 Faraday Avenue arlsbad, California 9 this form, together with a state be filed in each application impleted by one of the practition of the act on behalf of the assigned to the act of the act o	tement under 37 CFR 3 in which this form is us	.73(b) (Form PTO/SB/96 of the statement under the statement under the appointed by	or equivalent) Is r 37 CFR 3.73(b) ractitioner is
ny and an patriached to this ssignee No. 22 Co. A copy of to equired to	ent applications sasging as form in accordance with 37 CFR 3.736 ame and Address: 51S Pharmaceuticals, I 292 Faraday Avenue arlsbad, California 9 arlsbad, California 9 this form, together with a state be filled in each application impleted by one of the practitic to act on behalf of the assignation be filled.	tement under 37 CFR 3 in which this form is us ioners appointed in this nee, and must identify	.73(b) (Form PTO/SB/96 of sed. The statement under storm if the appointed pithe application in which	or equivalent) Is r 37 CFR 3.73(b) ractitioner is this Power of
A copy of tequired to authorized Attorney is	ent applications sasgined sold in accordance with 37 CFR 3.736 ame and Address: 51S Pharmaceuticals, I 292 Faraday Avenue arlsbad, California 9 arlsbad, California 9 this form, together with a state of the filed in each application is mpleted by one of the practitil to act on behalf of the assignation of the assignation is to be filed.	tement under 37 CFR 3 in which this form is us ioners appointed in this nee, and must identify	.73(b) (Form PTO/SB/96 of sed. The statement under storm if the appointed pithe application in which	or equivalent) Is r 37 CFR 3.73(b) ractitioner is this Power of
ny and an patrached to this ssignee No. Is signee No. 2.2 C.2 A copy of the equired to enay be consumally be consumally and the consumal to the consumal t	ent applications sasging as form in accordance with 37 CFR 3.736 ame and Address: 51S Pharmaceuticals, I 292 Faraday Avenue arlsbad, California 9 arlsbad, California 9 this form, together with a state be filled in each application impleted by one of the practitic to act on behalf of the assignation be filled.	tement under 37 CFR 3 in which this form is us ioners appointed in this nee, and must identify	.73(b) (Form PTO/SB/96 of the statement under statement in the appointed pithe application in which record altorized to act on behalf of the statement in the s	or equivalent) Is r 37 CFR 3.73(b) ractitioner is this Power of

This collection of information is required by 37 CFR 1.31 and 1.33. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentially is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any complete, including gathering, preparing, and submitting the complete dapplication for reducing this burden, should be sent to the Chief Information Officer, comments on the amount of lime you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer.

U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450.

FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1460.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

BEST AVAILABLE COPY

DT05 Rec'd PCT/PTO 0 1 DEC 2004

11/04/2004 13:53 FAX 7606033820

ISIS-PHARMACEUTICALS

→ HOWSON & HOWSON 2007/007

PTO/SR/86 (09-04) PTO/SE/96 (09-04)

Approved for use through 07/31/2006. OMB 0851-0031

U.S. Patent and Tredemark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

STATEMENT UI	NDER 37 CFR 3.73(b)
Applicant/Patent Owner: ISIS Pharmaceuticals, Inc.	
Application No./Patent No.:Filed/	ssue Data:
Entitled: Antisense Modulation of Extracellular-Signal-Regulated K	inase-6 Expression
1 3 S Pharmaceuticals, Inc. , a ex (Ty)	progration pe of Assignse, e.g., corporation, partnership, university, government agency, etc.)
states that it is: 1. the assignee of the entire right, title, and Interest; or	
 an assignee of less than the entire right, title and inte The extent (by percentage) of its ownership interest is 	rest. 5%
in the patent application/patent identified above by virtue of	
A. An assignment from the inventor(s) of the patent app in the United States Patent and Trademark Office at F thereof is attached.	lication/patent identified above. The assignment was recorded teel, Frame, or for which a copy
OR Ei. A chain of title from the Inventor(s), of the patent applied below:	ication/patent identified above, to the current assignee as shown
From: The document was recorded in the United State Reel, Frame	To: es Patent and Trademark Office at or for which a copy thereof is attached.
2. From:	, To:
2. From: The document was recorded in the United State Reel, Frame	es Patent and Tragemant Office at
3. From:	To:
The document was recorded in the United State Reel, Frame	es Patent and Trademark Office at or for which a copy thereof is attached.
Additional documents in the chain of title are listed	on a supplemental sheet.
☐ Copies of assignments or other documents in the chain [NOTE: A separate copy (i.e., a true copy of the original Division in accordance with 37 CFR Part 3, if the a MPEP 302.08]	of title are attached. I assignment document(s)) must be submitted to Assignment satignment is to be recorded in the records of the USPTO. See
'The undersigned (whose title is supplied below) is authorize	to act on behalf of the assignee.
Signature	Date
B. Lynn Pershall	T-leabana Negation
Printed or Typed Name	Telephone Number
Executive Vice President	

This collection of Information is required by 37 CFR 3.73(b). The information is required to obtain or retain a benefit by the public which is to file (and by the JSPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to late 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the Individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, J.S. Patent and Trademark Office. U.S. Department of Continerce, P.O. Box 1450. Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Rec'd PSWPTO 01 DEC 2004

11/04/2004 12:22 FAX 7606033820

ISIS-PHARMACEUTICALS

PTO/8B/01 (08-03) Approved for use through 07/31/2006. OMB 0651-0032 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no parsons are required to reapo flection of information unless it contains a valid OMB control number. Altomey Docket Number PTS-0055USA DECLARATION FOR UTILITY OR First Named Inventor DESIGN Bennett et al. PATENT APPLICATION COMPLETE IF KNOWN (37 CFR 1.63) Application Number unassigned Filing Date Declaration Declaration Herewith Submitted ÓR Submitted after Initial Art Unit With Initial Filing (surcharge unassigned Filing (37 CFR 1.16 (e)) Examiner Name required) unassigned I hereby declare that; Each inventor's residence, mailing address, and citizenship are as stated below next to their name. I believe the Inventor(s) named below to be the original and first inventor(s) of the subject matter which is claimed and for which a patent is sought on the invention entitled: Antisense Modulation of Extracellular Signal Regulated Kinase-6 Expression (Title of the Invention) the specification of which ~ is attached hereto OR was filed on (MM/DD/YYYY) as United States Application Number or PCT International Application Number and was amended on (MM/DD/YYYY) (if applicable). I hereby state that I have reviewed and understand the contents of the above Identified specification, including the claims, as amended by any amendment specifically referred to above. I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT international filing date of the continuation-in-part application. I hereby claim foreign priority benefits under 35 U.S.C. 119(a)-(d) or (f), or 365(b) of any foreign application(s) for patent, inventor's or plant breeder's rights certificate(s), or 365(a) of any PCT international application which designated at least one country other than the United States of America, listed below and have also identified below, by checking the box, any foreign application for patent, inventor's or plant breeder's rights certificate(s), or any PCT International application having a filing date before that of the application on which priority is claimed. Prior Foreign Application Foreign Filing Date Priority Certified Copy Attached? Number(s) Country (MM/DD/YYYY) Not Claimed Additional foreign application numbers are listed on a supplemental priority data sheet PTO/SB/028 attached hereto.

[Page 1 of 2]
This collection of information is required by 35 U.S.C. 115 and 37 CFR 1.83. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 21 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will very depending upon the individual case. Any comments on the amount of time you require to complete this form end/or suggestions for reducing this burden, should be sent to the Chief information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450. [Page 1 of 2]

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

→ HOWSON & HOWSON 2003/004

PTO/SB/01 (06-03)

Approved for use through 07/31/2003. OMB 0651-0032

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

DECLARATION — Utility or Design Patent Application

				$\overline{}$					
Direct all correspondence to:	Custom	er Numbe	or:	3844	1	OR		Corre	espondence address below
Name HOWSON AND HOWSON, Mary	E. Bak					-			
Address P.C. Box 457				_					
City				1 64	1				
Spring House				Sta	ate Insylva	nta			ZIP
Country		Telepho	no.	1	iiiayiva	Fax			19477
USA.		215-540-				1	540-58	18	
I hereby declare that all state and belief are believed to to statements and the like so me false statements may jeopardi	ede are ounisha	uier uiai. Na by fina	use eseru Anmino e	atome atome	ntsw	ere mad	8 With day 19	the la	
NAME OF SOLE OR FIRST	NVENTOR:			oetitio	n has	heen file	d for th	ie uneie	ned inventor
Given Name (first and middle [if any])					11.00	Family of Sum	Name	is urisin	ined myauról
Inventor's Signature C - Prom	Ben	net-							Date 11-28-01
Residence: City	State California			COU	intry		· · · · · · · · · · · · · · · · · · ·	Citize US	nship
Mairing Address 1347 Cassins Street							*	<u> </u>	
City	State				ZIP				Country
CAR: SBAD	California				9200	9			USA
NAME OF SECOND INVENTO	DR:				7 A	netition b	as bee	n filed f	or this unsigned inventor
Glyen Name (first and middle [if any]) (enneth W.						amily Na or Surnar	me		or and arrelation inventor
friventor's Signature	Zho	·							Date 10/28/04
Residence: City	State			Cou	ntry			Citizer	nship
Del Mar Malling Address	California		لب	USA		_		UK	
703 Stratford Court, #4									
City	State				ZIP			Count	у
Del Mar	California			ļ	92014		ſ	USA	
Additional Inventors or a legal re	oresentative are being	named on t	ine <u>1</u> s	upptem	vital sh	eet(s) PTO/	SB/02A	or 02! R =	tlached hereto.
						3-7: -97			THE PARTY OF THE P

[Page 2 of 2]

Ø 004/004

PTO/SB/02A (08-03)

Under the Paperwork Reduction Act of 1995, no persons are	required to	103DOUG TO B CO	necho	t and Trademark C P of information un	Mice; U.S. DEPAR	731/2003. OMB 0651- RTMENT OF COMME railed OMB control our	
DECLARATION		ADDITI Supplem	ONA	AL INVENTO	R(S)	ge <u>3</u> of 3	
Name of Additional Joint Inventor, if any:		□ Ap	etition	n has been filed t	for this unsigned	i inventor	
Given Name (first and middle (if any)				r Surname			
Erle 3.		Marcusson			· · · · · · · · · · · · · · · · · · ·		
Inventor's Em & Manuer					Date /	0/29/04	
San Dego Residence: City	Californ State		USA Co	untry	US Citizens		
8366 Caminim de Pastel Making Address					Guzansı	mp	
Mailing Address							
San Lilego	Calllo	_		92111	USA		
City	Stat	9		Zip	Count	ν	
Name of Additional Joint Inventor, If any:		☐ A pe	tition	has been filed fo	bengianu eldi x	inventor	
Given Name (first and middle (if any)		Family Name or Surname					
		 		rainly 14g/	ile or Sumame		
Inventor's Signature		Date					
Residence: Cily	State			Country		Citizenship	
Malling Address							
Mailing Address	· ·						
City							
	State			Zip	Country	<u>'</u>	
Name of Additional Joint Inventor, if any:		☐ A peti	tion h	as been filed for	this unsigned in	ventor	
Given Name (first and middle (if any)		Family Name or Surname					
<u> </u>							
nventor's Signature		Date					
Residence; City	State		П.	Country		Citizenship	
failing Address							
lailing Addrees							
elty	State			Zip	Country		
his collection of information is required by 35 U.S.C. 115 and 37 CF and by the USPTO to process) an application. Confidentiality is governmenter, including gathering, preparing, and submitting the complete omners on the amount of time you require to complete this form at U.S. Patent and Tradement Office, U.S. Department of Commerce, P.C. O THIS ADDRESS, SEND TO: Commissioner for Patents, P.O.	ed application	on form to the U	SPTO	d to obtain or retail R 1.14. This coffe . Time will vary de s burden, should b	n a benefit by the ction is estimated spending upon the	to lake 21 minutes to individual case. Any	

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.